Wave Life Sciences Company Description

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.

The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.

It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD).

The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD.

Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.

Wave Life Sciences Ltd.

Country	Singapore
Founded	2012
Industry	Biological Products, Except Diagnostic Substances
Employees	288
CEO	Paul B. Bolno

Contact Details

Address: Marina One East Tower Singapore, 018936 Singapore
Phone	65 6236 3388
Website	wavelifesciences.com

Stock Details

Ticker Symbol	1U5
Exchange	Frankfurt Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Paul B. Bolno	Chief Executive Officer
Kyle B. Moran	Chief Financial Officer
Kate Rausch	Head of Investor Relations